CN103816127A - 含有三取代甘油化合物的口服剂型 - Google Patents

含有三取代甘油化合物的口服剂型 Download PDF

Info

Publication number
CN103816127A
CN103816127A CN201310689824.XA CN201310689824A CN103816127A CN 103816127 A CN103816127 A CN 103816127A CN 201310689824 A CN201310689824 A CN 201310689824A CN 103816127 A CN103816127 A CN 103816127A
Authority
CN
China
Prior art keywords
dosage forms
solid dosage
pharmaceutical solid
tri
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310689824.XA
Other languages
English (en)
Chinese (zh)
Inventor
沃尔夫冈·里克特
卢茨·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell protection patent Limited by Share Ltd
Original Assignee
Alphaptose GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphaptose GmbH filed Critical Alphaptose GmbH
Publication of CN103816127A publication Critical patent/CN103816127A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201310689824.XA 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型 Pending CN103816127A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85815706P 2006-11-10 2006-11-10
US60/858,157 2006-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800417728A Division CN101610758A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Publications (1)

Publication Number Publication Date
CN103816127A true CN103816127A (zh) 2014-05-28

Family

ID=39092201

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310689824.XA Pending CN103816127A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型
CNA2007800417728A Pending CN101610758A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007800417728A Pending CN101610758A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Country Status (11)

Country Link
US (2) US20110110984A1 (https=)
EP (1) EP2091520B1 (https=)
JP (1) JP5352466B2 (https=)
CN (2) CN103816127A (https=)
AT (1) ATE546133T1 (https=)
AU (1) AU2007316588B2 (https=)
CA (1) CA2668919C (https=)
DK (1) DK2091520T3 (https=)
ES (1) ES2382756T3 (https=)
RU (1) RU2009121838A (https=)
WO (1) WO2008055996A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
CA2673040C (en) * 2006-12-20 2016-02-02 Universitaetsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
EP1952803A1 (en) * 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3530767A1 (de) 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE4000084A1 (de) 1990-01-03 1991-07-04 Medmark Pharma Gmbh Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts)
AU1827799A (en) * 1997-12-15 1999-07-05 Axia Therapeutics, Inc. Oral delivery formulation
DE19822509A1 (de) * 1998-05-19 1999-11-25 Medmark Pharma Gmbh Edelfosin zur Behandlung von Hirntumoren
DE19829448A1 (de) 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
ATE290384T1 (de) * 1998-12-21 2005-03-15 Inkeysa Sa Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Also Published As

Publication number Publication date
WO2008055996A1 (en) 2008-05-15
EP2091520B1 (en) 2012-02-22
AU2007316588B2 (en) 2013-11-21
JP5352466B2 (ja) 2013-11-27
AU2007316588A1 (en) 2008-05-15
JP2010509293A (ja) 2010-03-25
CA2668919C (en) 2015-11-03
US20170157150A1 (en) 2017-06-08
ES2382756T3 (es) 2012-06-13
CA2668919A1 (en) 2008-05-15
ATE546133T1 (de) 2012-03-15
DK2091520T3 (da) 2012-06-18
CN101610758A (zh) 2009-12-23
RU2009121838A (ru) 2010-12-20
US20110110984A1 (en) 2011-05-12
EP2091520A1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
Dixit Floating drug delivery system
TW200539902A (en) Oral pharmaceutical compositions of timed-release particles and tablets quickly disintegrable in the oral cavity containing compositions thereof
AU6279800A (en) Delayed-action form of administration containing tramadol saccharinate
Vasave A review on: floating drug delivery system
WO2007106960A1 (en) Controlled-release floating dosage forms
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
KR101050015B1 (ko) 위체류약물전달시스템을 이용한 애엽 추출물의 약학조성물및 이를 이용한 서방성 경구용 제제
JPS5857315A (ja) 製薬学的調製物
CZ194698A3 (cs) Orální farmaceutický přípravek obsahující 5-ASA s modifikovaným uvolňováním
ES2605650T3 (es) Formulación farmacéutica que contiene fosfatidilcolina para el tratamiento de la colitis ulcerativa
US20170157150A1 (en) Oral dosage form comprising tri-substituted glycerol compounds
EP1128826B1 (en) Chromone enteric release formulation
CN105267172B (zh) 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
JP2025519762A (ja) 抗凝血治療のための医薬組成物及びその応用
JP3103513B2 (ja) サメ軟骨経口摂取製剤
WO2017029225A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
RU2648353C2 (ru) Композиция в виде частиц и способ ее получения
JP2014530828A (ja) 有機化合物におけるまたは有機化合物に関連する改善
Roy Formulation and design of extended release matrix tablets of zidovudine hydrochloride: A study on effect of various grades of ethocel and hpmc
CN121925252A (zh) 用于口服给药的含有卡巴他赛和脂质的组合物
CN117717557A (zh) 一种包含伊布替尼药物组合物的制备方法
CN120076797A (zh) 包含去铁酮的调释药物制剂
KAVITHA The Tamilnadu Dr. MGR Medical University Guindy, Chennai-600032, Tamilnadu, India.
CN117752664A (zh) 一种包含伊布替尼晶型a的药物组合物及用途
Mathivanan Formulation and Evaluation of hydrodynamically balanced system of Baclofen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160317

Address after: Swiss Swiss

Applicant after: Cell protection patent Limited by Share Ltd

Address before: hamburg

Applicant before: Alphaptose GmbH

RJ01 Rejection of invention patent application after publication

Application publication date: 20140528

RJ01 Rejection of invention patent application after publication